Home » PERCEPTRONIX RECEIVES CE MARK FOR ITS CLEARSIGN SPUTUM TEST FOR EARLY LUNG CANCER
PERCEPTRONIX RECEIVES CE MARK FOR ITS CLEARSIGN SPUTUM TEST FOR EARLY LUNG CANCER
Perceptronix Medical Inc. May 26 announced receipt of CE Mark for its ClearSign Sputum Test for the detection of early lung cancer, allowing it to be marketed in the European Union.
Genetic Engineering News
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May